Wright S D, Ramos R A, Patel M, Miller D S
Rockefeller University, New York, New York 10021.
J Exp Med. 1992 Sep 1;176(3):719-27. doi: 10.1084/jem.176.3.719.
We have previously reported that lipopolysaccharide (LPS) binding protein (LBP) opsonizes endotoxin (LPS) for recognition by CD14 on phagocytes. Here we show that normal human plasma contains high titers of an activity that also binds LPS (Re, 595) and mediates recognition by CD14. Opsonization of LPS-coated particles with plasma enables the particles to be bound by phagocytes. Further, opsonization with plasma also enables subnanogram-per-milliliter concentrations of LPS to induce dramatic alterations in the function of leukocyte integrins on polymorphonuclear leukocytes and to induce secretion of tumor necrosis factor by monocytes, suggesting that opsonization by factors in plasma may be important in responses of cells to endotoxin. The opsonic activity in plasma appears distinct from LBP since it is not blocked by neutralizing antibodies against LBP. Surprisingly, the opsonic activity of plasma is not present in a single protein species, but at least two species must be combined to observe activity. Further, the opsonic activity of plasma for LPS is blocked by addition of protease inhibitors, suggesting that proteolytic activity or activities are required for opsonization. These properties are suggestive of the action of a protease cascade, but opsonic activity of plasma is not affected by blockade or depletion of either the complement or clotting cascades. We propose the name "septin" to describe this novel LPS-opsonizing activity in plasma.
我们之前曾报道,脂多糖(LPS)结合蛋白(LBP)可调理内毒素(LPS),使其被吞噬细胞上的CD14识别。在此我们表明,正常人血浆中含有高滴度的一种活性物质,它也能结合LPS(Re,595)并介导CD14的识别。用血浆对包被LPS的颗粒进行调理可使颗粒被吞噬细胞结合。此外,用血浆进行调理还能使每毫升亚纳克浓度的LPS诱导多形核白细胞上白细胞整合素功能发生显著改变,并诱导单核细胞分泌肿瘤坏死因子,这表明血浆中的因子进行调理可能在细胞对内毒素的反应中起重要作用。血浆中的调理活性似乎与LBP不同,因为它不会被抗LBP的中和抗体阻断。令人惊讶的是,血浆的调理活性并非存在于单一蛋白质中,而是至少两种物质必须结合才能观察到活性。此外,血浆对LPS的调理活性会因添加蛋白酶抑制剂而被阻断,这表明调理作用需要一种或多种蛋白水解活性。这些特性提示存在蛋白酶级联反应,但血浆的调理活性不受补体或凝血级联反应的阻断或消耗的影响。我们提议用“septin”这个名称来描述血浆中这种新的LPS调理活性。